Claims for Patent: 5,820,862

Summary for Patent: 5,820,862

Title:	T cell epitopes of the major allergens from dermatophagoides (house dust mite)
Abstract:	The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.
Inventor(s):	Garman; Richard D. (Arlington, MA), Greenstein; Julia L. (West Newton, MA), Kuo; Mei-chang (Winchester, MA), Rogers; Bruce L. (Belmont, MA), Franzen; Henry M. (Watertown, MA), Chen; Xian (North Chelmsford, MA), Evans; Sean (Acton, MA), Shaked; Ze\'ev (Berkeley, CA)
Assignee:	Immulogic Pharmaceutical Corporation (Waltham, MA)
Application Number:	08/482,142
Patent Claims:	1. A therapeutic composition comprising at least one isolated peptide selected from the group consisting of: DPI-21.2 (SEQ ID NO:28) and DFI-22.2 (SEQ ID NO:93), and at least one isolated peptide selected from the group consisting of: DPI-23.31 (SEQ ID NO:165), DPI-26.6 (SEQ ID NO:168), DPII-20.9 (SEQ ID NO:169), DPII-22.14 (SEQ ID NO:180) and DPII-25.15 (SEQ ID NO:188). 2. A therapeutic composition comprising the following isolated peptides: DPI-21.2 (SEQ ID NO:28), DFI-22.2 (SEQ ID NO:93), DPI-23.31 (SEQ ID NO:165), DPI-26.6 (SEQ ID NO:168), DPII-22.14 (SEQ ID NO:180)) and DPII-25.15 (SEQ ID NO: 188). 3. A method of treating sensitivity to house dust mite allergen in a mammal comprising administering simultaneously or sequentially at least two different compositions of claim 1. 4. A method of treating sensitivity to house dust mite allergen in a mammal comprising administering a therapeutic composition of claim 2. 5. A multipeptide formulation for pharmaceutical administration comprising at least one isolated peptide selected from the group consisting of: DPI-21.2 (SEQ ID NO:28) and DFI-22.2 (SEQ ID NO:93), and at least one isolated peptide selected from the group consisting of: DPI-23.31 (SEQ ID NO:165)), DPI-26.6 (SEQ ID NO: 168), DPII-20.9 (SEQ ID NO:169), DPII-22.14 (SEQ ID NO:180) and DPII-25.15 (SEQ ID NO:188), each peptide being soluble and stable at a physiologically acceptable predetermined pH, and wherein said formulation comprises a sufficient percentage of T cell epitopes of a house dust mite allergen selected from the group consisting of Der p I, Der p II Der f I and Der f II, such that upon administration of the multipeptide formulation to an individual sensitive to house dust mites, T cells of the individual are tolerized to said house dust mite allergen; and a pharmaceutically acceptable carrier. 6. The multipeptide formulation of claim 5 further comprising EDTA. 7. The multipeptide formulation of claim 5 further comprising a pharmaceutically acceptable counter ion. 8. The multipeptide formulation of claim 5 wherein said predetermined pH is a pH in the range of pH 6.0 to pH 8.0. 9. The multipeptide of claim 5 wherein said sufficient percentage of T cell activity is at least 37%. 10. The multipeptide formulation of claim 5 comprising the following isolated peptides: DPI-21.2 (SEQ ID NO:28), DFI-22.2 (SEQ ID NO:93), DPI-23.31 (SEQ ID NO:165), DPI-26.6 (SEQ ID NO:168), DPII-22.14 (SEQ ID NO:180) and DPII-25.15 (SEQ ID NO:188). 11. The multipeptide formulation of claim 5 further comprising the isolated peptide, DPII-20.9 (SEQ ID NO:169). 12. An optimized multipeptide formulation suitable for therapeutic treatment of humans suffering from allergy to house dust mite comprising: isolated peptides DPI-21.2 (SEQ ID NO:28), DFI-22.2 (SEQ ID NO:93), DPI-23.31 (SEQ ID NO:165), DPI-26.6 (SEQ ID NO:168), DPII-22.14 (SEQ ID NO:180) and DPII-25.15 (SEQ ID NO:188), each peptide in a concentration of 0.75 mg per peptide; 0.05M sodium phosphate U.S.P.; 5 w/v Mannitol, U.S.P.; 0.1 mg/ml EDTA disodium dihydrate U.S.P.; and Sterile Water for injection U.S.P; wherein said formulation has a final pH of 7.2-7.4. 13. An optimized multipeptide formulation of claim 12 further comprising the isolated peptide, DPII-20.9 (SEQ ID NO:169). 14. An optimized multipeptide formulation suitable for therapeutic treatment of humans suffering from allergy to house dust mite comprising: isolated peptides DFI-22.2 (SEQ ID NO:93), DPI-23.31 (SEQ ID NO:165), and DPII-22.14 (SEQ ID NO:180), each peptide in a concentration of 0.75 mg per peptide; 0.05M sodium phosphate U.S.P.; 5% w/v Mannitol, U.S.P.; 0.1 mg/ml EDTA disodium dihydrate U.S.P.; and Sterile Water for injection U.S.P; wherein said formulation has a final pH of 7.0. 15. An optimized multipeptide formulation suitable for therapeutic treatment of humans suffering from allergy to house dust mite comprising: isolated peptides DPI-21.2 (SEQ ID NO:28), DPI-26.6 (SEQ ID NO: 168), and DPII-25.15 (SEQ ID NO:188), each peptide in a concentration of 0.75 mg per peptide; 0.05M sodium phosphate U.S.P.; 5% w/v Mannitol, U.S.P.; 0.1 mg/ml EDTA disodium dihydrate U.S.P.; and Sterile Water for injection U.S.P; wherein said formulation has a final pH of 6.2. 16. A method of treating sensitivity to house dust mite allergy in an individual comprising administering an optimized multipeptide formulation of claim 12. 17. A method of treating sensitivity to house dust mite allergy in an individual comprising administering simultaneously or sequentially, as a single treatment episode, first and second optimized multipeptide formulations wherein said first formulation comprises: isolated peptides DFI-22.2 (SEQ ID NO:93, DPI-23.31 (SEQ ID NO:165), and DPII-22.14 (SEQ ID NO:180), each peptide in a concentration of 0.75 mg per peptide; 0.05M sodium phosphate U.S.P.; 5% w/v Mannitol, U.S.P.; 0.1 mg/ml EDTA disodium dihydrate U.S.P.; and Sterile Water for injection U.S.P; having a final pH of 7.0; and wherein said second optimized multipeptide formulation comprises: isolated peptides DPI-21.2 (SEQ ID NO:28), DPI-26.6 (SEQ ID NO:168, and DPII-25.15 (SEQ ID NO:188), each peptide in a concentration of 0.75 mg per peptide; 0.05M sodium phosphate U.S.P.; 5% w/v Mannitol, U.S.P.; 0.1 mg/ml EDTA disodium dihydrate U.S.P.; and Sterile Water for injection U.S.P; having a final pH of 6.2. 18. An isolated peptide having an amino acid sequence selected from the group consisting of DPI-21.2 (SEQ ID NO:28), DFI-22.2 (SEQ ID NO:93), DPI-23.31 (SEQ ID NO:165), DPI-26.6 (SEQ ID NO:168), DPII-20.9 (SEQ ID NO:169), DPII-22.14 (SEQ ID NO:180) and DPII-25.15 (SEQ ID NO:188). 19. A therapeutic composition comprising at least one isolated peptide selected from the group consisting of: DPI-21.1 (SEQ ID NO:27), DPI-21.2 (SEQ ID NO:28), DFI-22.2 (SEQ ID NO:93), DPI-23.31 (SEQ ID NO:29), DPI-26.6 (SEQ ID NO:168), DPII-22.4 (SEQ ID NO:37), DPII-20.9 (SEQ ID NO:31) and DPII-25.15 (SEQ ID NO:188). 20. A therapeutic composition of claim 19 comprising at least two of said isolated peptides. 21. A therapeutic composition comprising the following isolated peptides: DPI-21.2 (SEQ ID NO:28), DPI-26.6 (SEQ ID NO:168), and DPII-25.15 (SEQ ID NO:50188).

Details for Patent 5,820,862

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2015-10-13